News Headlines

  1. MannKind And Rose Pharma Inc Enter Licensing And Collaboration Agreement To Develop An Inhaled Rapid-Acting, Short-Duration GLP-1 For Weight Management 9/9/2026

    MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, and Rose Pharma Inc. (Rose Pharma) today announced that they have entered into a worldwide licensing and collaboration agreement to develop ROSE-010 Technosphere for weight management.

  2. Ensera Forges Strategic Alliance With American Injectables 9/8/2026

    Ensera, a global leader in contract design, contract manufacturing, and packaging services for the pharmaceutical and medical device industries, today announced a strategic alliance with American Injectables, a Florida-based CDMO specializing in the fill-finish of sterile injectable drugs.

  3. HCW Biologics Entered An Exclusive Distribution Agreement With Akron Biotech To Commercialize HCW11-006 As Reagent Used To Support Production Of Highly Functional Human CAR-T Cells 9/8/2026

    HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, announced today that the Company has entered into an Exclusive Distribution Agreement with Akron Biotech (“Akron”), a leading manufacturer of ancillary materials and a contract development and manufacturing organization for the cell, gene therapy, and regenerative medicine industries, for the commercialization of HCW11-006 for use as a reagent to support a new method of producing highly functional human CAR-T cells for treating cancer, autoimmune disease, and infectious diseases.

  4. Transgene And ProBioGen Expand Strategic Partnership With Additional License Agreement For AGE1.CR.pIX Cell Line 9/8/2026

    Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a leading contract development and manufacturing organization (CDMO) in biologics, vaccines and viral vectors, today announce that the companies have broadened the scope of their existing collaboration.

  5. eXoZymes Selects Curia As Commercial-Scale Manufacturing Partner For NCT 9/8/2026

    Today, eXoZymes Inc. (“eXoZymes”) - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced that it has entered into an agreement with Curia Global, Inc. (“Curia”), a global leader in contract manufacturing, to initiate technology transfer and scale-up activities for N-trans-caffeoyltyramine (“NCT”).

  6. Biocon Secures 10-Year Supply Contract For Pertuzumab In Brazil 9/8/2026

    Biocon Limited, an innovation-led global biopharmaceuticals company, today announced the signing of partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil, marking an important milestone in advancing production and commercialisation of the HER2-positive breast cancer therapy under the country’s Productive Development Partnership (PDP) program.

  7. SpiroChem And ITM Announce Strategic Discovery Collaboration To Expand ITM's Radiopharmaceutical Pipeline 9/8/2026

    SpiroChem AG (SpiroChem), a Swiss Partner Research Organization specializing in complex medicinal chemistry, and ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced a strategic drug discovery collaboration to advance a novel radiopharmaceutical candidate for ITM’s pipeline.

  8. Aptar And Aceso Therapeutics Announce Collaboration To Advance Inhaled Antisense Oligonucleotide Therapy For Cystic Fibrosis 9/7/2026

    Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced a collaboration with Aceso Therapeutics, a biotech developing novel therapies for cystic fibrosis (CF), a rare genetic disease, to advance the development of ACT-101, an antisense oligonucleotide (ASO) candidate designed to target the underlying disease mechanisms of CF.

  9. Gan & Lee And Menarini Group Partner To Advance Bofanglutide In Europe 9/3/2026

    Gan & Lee Pharmaceuticals ("Gan & Lee"; stock code: 603087.SH) announced that it has entered into an exclusive license agreement with the multinational biopharmaceutical company The Menarini Group ("Menarini").

  10. HUTCHMED Announces Licensing Agreement With GSK For KRAS-EGFR-Antibody Conjugate Cancer Therapy 9/3/2026

    HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its subsidiary, HUTCHMED Limited, has entered into an exclusive development and license agreement with a subsidiary of GSK plc (“GSK”), granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830.